Drawing on expertise in the melanocortin family of peptides and photomedicine, diversify towards a sustainable biopharmaceutical group with multiple products treating multiple indications
As announced in November 2024, the priority is on:
Plans in each of these areas are outlined in the Operating Review. The strategy is being executed using an integrated business model with many of the key functions of a biopharmaceutical undertaken in-house.
Investor Relations will continue to communicate CLINUVEL’s compelling investment proposition through a range of channels, including conference presentations, investor briefings, group and one-on-one meetings, social media, webinars and podcasts.
Activities to advance the recognition of CLINUVEL’s story, brand and innovation, particularly to health-conscious households, will continue. CLINUVEL will present to numerous investor conferences and has already commenced planning its participation in the AAD Meeting to be held in Denver, Colorado, in March 2026. These activities will be complemented by digital campaigns by CLINUVEL Ambassadors, social media targeted advertisements, and articles in tier one media outlets.
CLINUVEL is committed to better integrating its supply chain. The Company has communicated this capability could be built in-house or progressed through strategic acquisitions.
Over the course of the 2020s to date, CLINUVEL has communicated its intention to grow inorganically through acquisition, conditional on an appropriate target being identified and satisfactory due diligence completed.
On 22 August 2025, the Company announced its intention to upgrade is American Depositary Receipt program in the U.S.A from Level I to Level II, listed on Nasdaq. This is expected to occur by the end of 2025, subject to successful completion of review by the Securities Exchange Commission and satisfaction of further listing requirements. The initiative reflects the significance of CLINUVEL’s American shareholder base at 28% of issued capital and increasing interest of potential U.S. institutional investors as CLINUVEL’s profile rises from its activities in EPP and vitiligo, and the relationship building efforts of Investor Relations. The Company is 65% owned by foreign entities versus 35% Australian. CLINUVEL’s visibility in the U.S., trading access and investor engagement will be enhanced. No capital raising is proposed and CLINUVEL’s primary ASX listing will remain unchanged.